Published in J Clin Oncol on September 01, 1999
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer | NCT03659578
Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer | NCT04275687
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol (2012) 1.72
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys (2009) 1.64
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer (2011) 1.63
Synchronous chemoradiation for squamous carcinomas. BMJ (2001) 1.61
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol (2012) 1.39
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol (2009) 1.34
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol (2011) 1.32
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer (2013) 1.31
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer (2003) 1.20
The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 1.14
Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol (2005) 1.13
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat (2010) 1.12
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer (2001) 1.10
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.07
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer (2003) 1.06
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist (2011) 1.06
A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis (2011) 1.01
Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer (2002) 1.00
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res (2015) 0.99
NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer (2006) 0.98
Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol (2012) 0.98
Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. J Thorac Dis (2011) 0.98
The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer. J Cancer Res Clin Oncol (2011) 0.98
Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer. Radiat Oncol J (2011) 0.95
Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res (2010) 0.95
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol (2008) 0.95
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer. Cancer Res Treat (2011) 0.93
Surgical management of advanced non-small cell lung cancer. J Thorac Dis (2014) 0.92
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol (2014) 0.91
¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Radiat Oncol (2012) 0.91
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist (2012) 0.91
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg (2012) 0.89
Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). Radiat Oncol (2015) 0.89
Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer (2006) 0.88
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer (2002) 0.88
Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Oncol (2007) 0.87
Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol (2013) 0.87
Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience. Lung India (2013) 0.87
Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer. Ann Thorac Med (2013) 0.86
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med (2013) 0.86
Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys (2012) 0.86
Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol (2008) 0.86
Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer. Cancer J (2013) 0.86
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer. J Thorac Oncol (2012) 0.85
Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. Radiat Oncol (2007) 0.85
Time to treatment in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2009) 0.85
Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer (2009) 0.85
Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res (2012) 0.84
A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiat Oncol (2006) 0.84
Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer (2006) 0.84
Lung cancer 7: management of lung cancer in elderly patients. Thorax (2003) 0.84
Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol (2017) 0.84
The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol (2014) 0.83
Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. Radiat Oncol J (2013) 0.83
Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. PLoS One (2015) 0.83
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiat Oncol (2011) 0.83
Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. Br J Cancer (2010) 0.83
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. Int J Clin Oncol (2005) 0.82
Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients. Ann Transl Med (2016) 0.82
A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. J Radiat Res (2012) 0.82
Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer (2014) 0.82
The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells. Sci Rep (2015) 0.82
Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non-small cell lung cancer. J Radiat Res (2016) 0.82
High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med (2006) 0.82
Treatment recommendations for locally advanced, non-small-cell lung cancer: the influence of physician and patient factors. Int J Radiat Oncol Biol Phys (2009) 0.81
DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume. Radiat Oncol (2013) 0.81
Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother (2013) 0.81
Phase I Study to Determine MTD of Docetaxel and Cisplatin with Concurrent Radiation Therapy for Stage III Non-Small Cell Lung Cancer. Chin J Cancer Res (2011) 0.81
High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol (2013) 0.80
Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung (2007) 0.80
Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol (2008) 0.80
Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. Balkan Med J (2014) 0.80
Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond. Front Oncol (2014) 0.80
High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study. Oncol Lett (2011) 0.80
Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning. Int J Radiat Oncol Biol Phys (2013) 0.80
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer (2006) 0.80
A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer (2015) 0.80
A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs (2001) 0.79
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol (2011) 0.79
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer (2015) 0.79
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol (2015) 0.79
Results of curative radiation therapy with or without chemotherapy for stage III unresectable non-small cell lung cancer. Cancer Res Treat (2005) 0.79
Pulmonary resection after chemoradiotherapy for advanced non-small cell lung cancer: the impact of presurgical radiation therapy. Surg Today (2013) 0.79
Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival? J Thorac Dis (2016) 0.78
From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions. Chemother Res Pract (2010) 0.78
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol (2008) 0.78
Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer. Radiat Oncol (2014) 0.78
VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 8.87
Nrl is required for rod photoreceptor development. Nat Genet (2001) 5.68
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem (2001) 4.51
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 3.69
Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet (2001) 3.14
Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem (1987) 2.94
Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem (1996) 2.72
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol (1992) 2.58
Fibronectin receptor structures in the VLA family of heterodimers. Nature (1987) 2.54
Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44
Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver. Hepatology (2000) 2.43
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology (2000) 2.36
Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem (1988) 2.20
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet (2008) 2.15
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol (1998) 2.12
The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. Proc Natl Acad Sci U S A (1987) 2.11
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol (2001) 2.10
Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol (1993) 2.08
Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation (1998) 2.05
Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation (2001) 2.04
Accumulation of GTP-bound RhoA during cytokinesis and a critical role of ECT2 in this accumulation. J Biol Chem (2000) 2.04
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol (1993) 2.02
Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem (1991) 2.01
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol (1999) 1.91
Treatment of gallbladder cancer by radical resection. Br J Surg (1999) 1.88
Ehrlichia muris sp. nov., identified on the basis of 16S rRNA base sequences and serological, morphological, and biological characteristics. Int J Syst Bacteriol (1995) 1.86
In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science (1991) 1.85
Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood (1999) 1.84
Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev (1990) 1.83
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer (2001) 1.81
Western immunoblot analysis of Haemobartonella muris and comparison of 16S rRNA gene sequences of H. muris, H. felis, and Eperythrozoon suis. J Clin Microbiol (1997) 1.80
A gene (sleB) encoding a spore cortex-lytic enzyme from Bacillus subtilis and response of the enzyme to L-alanine-mediated germination. J Bacteriol (1996) 1.79
Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol (1990) 1.78
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75
Integrins alpha2beta1 and alpha4beta1 can mediate SA11 rotavirus attachment and entry into cells. J Virol (2000) 1.72
p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res (1992) 1.72
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene (2006) 1.68
A germination-specific spore cortex-lytic enzyme from Bacillus cereus spores: cloning and sequencing of the gene and molecular characterization of the enzyme. J Bacteriol (1996) 1.65
New Ehrlichia species closely related to Ehrlichia chaffeensis isolated from Ixodes ovatus ticks in Japan. J Clin Microbiol (2000) 1.64
Interstitial lung disease associated with drug therapy. Br J Cancer (2004) 1.64
Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2000) 1.63
The function and distinctive regulation of the integrin VLA-3 in cell adhesion, spreading, and homotypic cell aggregation. J Biol Chem (1993) 1.59
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem (1996) 1.57
Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg (2000) 1.57
Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res (1999) 1.56
Epidemiology of sarcoidosis in Japan. Eur Respir J (2007) 1.54
Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem (1996) 1.53
RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem (2000) 1.53
DNA methylation profiles of lung tumors. Mol Cancer Ther (2001) 1.53
Long-term outcome of adult-to-adult living donor liver transplantation for post-Kasai biliary atresia. Am J Transplant (2006) 1.53
The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene (1991) 1.51
Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest (1998) 1.51
Altered rate of fibronectin matrix assembly by deletion of the first type III repeats. J Cell Biol (1996) 1.49
[Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi (1987) 1.48
Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A (2001) 1.48
Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat. J Biol Chem (2000) 1.48
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol (2004) 1.48
Casting behavior of titanium alloys in a centrifugal casting machine. Biomaterials (2003) 1.48
Changing ligand specificities of alphavbeta1 and alphavbeta3 integrins by swapping a short diverse sequence of the beta subunit. J Biol Chem (1997) 1.45
Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene (1991) 1.45
MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene (1993) 1.44
Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem (2000) 1.43
Expression of a germination-specific amidase, SleB, of Bacilli in the forespore compartment of sporulating cells and its localization on the exterior side of the cortex in dormant spores. J Bacteriol (1999) 1.43
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer (2005) 1.41
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol (1992) 1.40
Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol (1993) 1.40
Characteristics of hepatic alanine-glyoxylate aminotransferase in different mammalian species. Biochem J (1978) 1.40
Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. Nephron (2001) 1.39
The effect of 1,24(R)(OH)2D3 cream and ointment on epidermal proliferation and differentiation in mice. Dermatology (1996) 1.39
Correlations between platelet aggregation, fibrinolysis, peripheral and central serotonergic measures in subhuman primates. Atherosclerosis (1994) 1.39
Inhibition of cell cycle progression by the alternatively spliced integrin beta 1C. Science (1995) 1.38
Current practice of management of bacteremic sepsis: a study in a tertiary care teaching hospital in Japan. Intern Med (2000) 1.38
EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol (2005) 1.38
Impact of coronary artery remodeling on clinical presentation of coronary artery disease: an intravascular ultrasound study. J Am Coll Cardiol (2001) 1.37
Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. Int J Tuberc Lung Dis (2011) 1.37
Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res (1999) 1.35
Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem (1998) 1.35
Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem (2001) 1.32
Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29) Biochem J (1995) 1.32
Endurance exercise causes interaction among stress hormones, cytokines, neutrophil dynamics, and muscle damage. J Appl Physiol (1985) (1999) 1.32
Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem (2000) 1.31
Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience (1997) 1.30
Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1. Biochem J (1998) 1.29
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer (2007) 1.29